Assistant Professor, Family Medicine, Mayo Medical School
Cardiology
Dr. John A. Schirger, MD
|
|
Give Review
John A. Schirger, MD is an expert in the field of Cardiology. He attended Creighton University School of Medicine. Creighton University School of Medicine is ranked 79 in research and 78 in primary care medicine John A. Schirger is a published doctor. He has 44 papers published. The most current publication "Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin." John A. Schirger, MD is registered with Medicare.
Publications
- Chronic Peptide Therapy With B-Type Natriuretic Peptide in Patients With Preclinical Diastolic Dysfunction (Stage B Heart Failure).
- Uncorrected pre-operative mitral Valve regurgitation is not associated with adverse outcomes after continuous-flow left ventricular assist device implantation.
- Cardiac transplantation for radiation-induced Cardiomyopathy: the mayo clinic experience.
- Cardiac fibrosis in end-stage human Heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications.
- Early Trends in N-Terminal Pro-Brain Natriuretic Peptide Values After Left Ventricular Assist Device Implantation for Chronic Heart Failure.
- Preoperative Atrial Fibrillation Increases Risk of Thromboembolic Events After Left Ventricular Assist Device Implantation.
- Rationale and design of a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of B-type natriuretic Peptide for the preservation of le...
- Donor-Specific Antibodies to Class II Antigens Are Associated With Accelerated Cardiac Allograft Vasculopathy: A Three-Dimensional Volumetric Intravascular Ultrasound ...
- Predictive value of the model for end-stage liver Disease score in patients undergoing left ventricular assist device implantation.
- Novel protein therapeutics for systolic heart failure: Chronic subcutaneous B-type natriuretic Peptide.
- Readmissions after implantation of axial flow left ventricular assist device.
- Implantation of a HeartMate II Left Ventricular Assist Device via Left Thoracotomy.
- Usefulness of the six-minute walk test after continuous axial flow left ventricular device implantation to predict survival.
- Changes in renal function after implantation of continuous-flow left ventricular assist devices.
- Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy with Improved Late Survival and Decreased Cardiac Events Following Cardiac Transplantation.
- Impaired natriuretic and renal endocrine response to Acute volume expansion in pre-clinical systolic and diastolic dysfunction.
- Echocardiographic Variables Post LVAD Associated with Adverse Outcome.
- Cardiac allograft hypertrophy is associated with impaired exercise tolerance after Heart transplantation.
- Echocardiographic predictors of adverse outcomes after continuous left ventricular assist device implantation.
- LVAD Therapy in Patients with Restrictive and Hypertrophic Cardiomyopathy.
- Echocardiographic findings in stable outpatients with properly functioning HeartMate II left ventricular assist devices.
- Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental Heart failure.
- Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and Acute actions in angiotensin II-mediated hypertension.
- Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improv...
- Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure.
- Equimolar doses of Atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure.
- Natriuretic and antialdosterone actions of Chronic oral NEP inhibition during progressive congestive heart failure.
- Atrial BNP endocrine function during chronic unloading of the normal canine heart.
- Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental Heart failure.
- Endothelin A receptor antagonism in experimental congestive Heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention.
- Subcutaneous administration of brain natriuretic peptide in experimental Heart failure.
- Modulation of functionally active endothelin-converting enzyme by Chronic neutral endopeptidase inhibition in experimental atherosclerosis.
- Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition.
- Renal response to Acute neutral endopeptidase inhibition in mild and severe experimental heart failure.
- Renal actions of synthetic dendroaspis natriuretic peptide.
- Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human Heart failure.
- Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin.
- Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin.
- Enhanced endothelin-converting enzyme immunoreactivity in early atherosclerosis.
- Congestive Heart failure: pharmacological agents and the potential of B-type natriuretic Peptide.
- Caveat medicus! Pulmonary hypertension in the elderly: a word of caution.
- Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study.
- Intact Acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure.
Schools
Creighton University
Procedures Preformed
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac Myocardial Perfusion Imaging
- Cardioversion, Elective
- View All
Conditions Treated
- Acute Venous Embolism Thrombosis
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Valve Disease
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
Education
-
Mayo School of Graduate Medical Education -
Creighton University School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1174597876 | |
| NPPES Provider LastName | SCHIRGER | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 672.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1174597876 |
| Last Name Of The Provider | SCHIRGER |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. Margaret A. Lloyd, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Bradley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sharonne N. Hayes, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Pankaj Madan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Abhiram Prasad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mothilal S. Jain, MD |
|
|
Dr. Theophilus E. Owan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert F. Rea, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Donald L. Johnston, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francisco L. Jimenez, MD |